Skip to main content
. 2020 Apr 19;28(7):1569–1584. doi: 10.1016/j.ymthe.2020.04.018

Figure 1.

Figure 1

mRNA-Lipid Nanoparticle Vaccine Platform Utilized for the Delivery of a Combination of Conserved Influenza Virus Antigens

(A) Schematic representation of the mRNA-lipid nanoparticle vaccine technology that incorporates a 1-methylpseudouridine-modified mRNA molecule into an 80 lipid nanometer vesicle for efficient delivery into host cells upon vaccination. (B) Diagrams illustrating the antigens used as immunogens in this study. Amino acid numbers are included under the mRNA coding for each antigen. Not drawn to scale.